BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies (NASDAQ: BSGM) and Streamex Exchange Corporation have appointed Mitch Williams, CFA, as their Chief Investment Officer. Williams, a former executive at OppenheimerFunds and Wafra Inc., brings over 20 years of capital markets experience to the combined company. At Wafra Inc., he achieved more than 3-fold growth in Global Equity assets and delivered top-quartile performance consistently.

As CIO, Williams will lead the companies' strategic vision and commodity tokenization initiatives, focusing on penetrating the $142.85 trillion global commodity market through real world asset (RWA) tokenization solutions. He will report directly to CEO Henry McPhie. Williams, who was previously an early investor and Strategic Advisor to Streamex, views RWA tokenization as a scalable technology and sees Streamex as a unique investment opportunity combining fiat currency hedging with recurring revenue.

BioSig Technologies (NASDAQ: BSGM) has appointed Mitch Williams, CFA, as Chief Investment Officer following its acquisition of Streamex Exchange Corporation. Williams, a former executive at OppenheimerFunds and Wafra Inc., brings over 20 years of capital markets experience to advance the company's mission in real world asset tokenization and commodity markets.

At Wafra Inc., Williams demonstrated exceptional performance by growing assets more than 3-fold and maintaining top-quartile performance. At OppenheimerFunds, he was the top-ranked equity analyst leading the firm's flagship fund. In his new role, Williams will oversee the company's strategic vision and commodity tokenization initiatives within the $142.851 trillion global commodity market, reporting directly to CEO Henry McPhie.

BioSig Technologies (NASDAQ: BSGM) and Streamex Exchange Corporation have completed their share exchange transaction, transforming into a company focused on real-world asset tokenization, particularly in the commodities sector. The deal positions the combined entity to tap into the $142.85 trillion global commodity market.

Key leadership changes include Streamex's Co-Founder Henry McPhie becoming CEO and joining the Board, while Co-Founder Morgan Lekstrom will serve as Chairman. Former BioSig CEO Anthony Amato will remain on the Board. Notable strategic additions include Frank Giustra, founder of Wheaton Precious Metals and GoldCorp, as Strategic Investor and Advisor on Commodities, and Mathew August as Strategic Advisor on US Capital Markets.

BioSig Technologies (NASDAQ: BSGM) has signed a definitive share exchange agreement with Streamex Exchange Corporation, marking a significant pivot from medical technology to real-world asset tokenization. Under the agreement, Streamex will become a wholly-owned subsidiary of BioSig, with Streamex shareholders receiving 75% of BioSig's fully diluted common stock. The combined company will be led by Streamex's Co-Founder Henry McPhie as CEO, while Morgan Lekstrom will serve as Chairman.

The transaction brings notable strategic advisors, including Frank Giustra, founder of Wheaton Precious Metals and GoldCorp, positioning the company to tap into the $142.85 trillion global commodity market through blockchain technology. Initially, Streamex shareholders will receive 19.9% of BioSig's outstanding common stock, with the full 75% stake subject to shareholder approval.

BioSig Technologies (NASDAQ: BSGM) has signed a Letter of Intent (LOI) to merge with Streamex Exchange Corporation in an all-stock transaction. The merger aims to create a publicly listed real-world asset tokenization company on the Nasdaq. Streamex offers a technology stack featuring a fully developed primary issuance and decentralized exchange infrastructure for on-chain commodity markets. The platform provides commodity-focused real-world asset tokenization infrastructure and a financing platform designed to streamline the investment process, increase capital availability, and expand investor opportunities.

BioSig Technologies (BSGM) has successfully regained full compliance with Nasdaq Capital Market listing requirements. The company received formal notice on March 24, 2025, confirming it has met the minimum stockholders' equity threshold of $2.5 million as per Listing Rule 5550(b), resolving its previously disclosed deficiency.

The medical technology company, known for its PURE EP™ Platform that provides precision in intra-cardiac signal visualization for electrophysiologists during ablation treatments of cardiovascular arrhythmias, maintains its focus on advancing operational goals and strengthening market position through innovation and strategic partnerships.

BioSig Technologies (NASDAQ: BSGM) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or more for at least 10 consecutive business days, meeting Nasdaq Listing Rule 5550(a)(2) requirements. Nasdaq has officially closed the prior bid price deficiency matter as of November 13, 2024. The company's PURE EP™ Platform, which is FDA 510(k) cleared, provides real-time cardiac signal visualization for targeted cardiac ablation procedures.

BioSig Technologies, Inc. (OTCQB: BSGM) has successfully appealed to the NASDAQ Panel, resulting in the resumption of its common stock trading on the NASDAQ Capital Market Exchange on October 23, 2024. The company was granted an extension until March 7, 2025, providing a 360-day grace period to meet the Market Value of Listed Securities (MVLS) requirement.

CEO Anthony Amato expressed gratitude to Nasdaq, the company's attorneys, advisors, and shareholders for their support during this challenging year. He emphasized that this development is positive for the company and its commitment to restoring shareholder value.

BioSig Technologies is a medical technology company focused on deciphering electrical signals, particularly heart rhythms. Their FDA 510(k) cleared PURE EP™ Platform provides superior, real-time signal visualization for cardiac ablation procedures, aiming to improve efficiency and efficacy in healthcare.

BioSig Technologies (OTCQB: BSGM) has announced its intent to acquire the assets of Neuro-Kinesis (NKC), a private medical technology company developing smart EP tools. The acquisition will be paid through BioSig's common stock, with NKC providing $2.5-$6 million in unrestricted cash to BioSig at closing. The deal aims to expand BioSig's product portfolio beyond PURE EP™.

NKC's key technologies include the Huygens™ Catheter, which improves signal detection resolution, and the Proteus™ Robotic Arm, offering computer-assisted robotic guidance for EP procedures. These innovations address limitations in existing EP mapping technology, potentially improving the treatment of complex arrhythmias.

The acquisition is subject to due diligence and shareholder approval. NKC brings a strong management team, extensive IP portfolio, and AI capabilities to enhance EP mapping systems.